Oleclumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | 5'-nucleotidase NT5E |
| Clinical data | |
| Other names | MEDI9447 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6348H9826N1710O1998S40 |
| Molar mass | 143350.81 g·mol−1 |
Oleclumab (INN;[1] development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73[2] that was designed for the treatment of pancreatic and colorectal and other cancers.[3]
This drug was developed by MedImmune/AstraZeneca.[4]
References
[edit]- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ↑ Kowash RR, Akbay EA (2023). "Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer". Frontiers in Immunology. 14 1130358. doi:10.3389/fimmu.2023.1130358. PMC 10079876. PMID 37033953.
- ↑ ClinicalTrial.gov for Oleclumab
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information. |